Article Versions Notes

Van den Bosch J, Caz N, Martens S, Erens C, Rasking L, Gervois P, Nijsten K, Himmelreich U, Van Cauter S, Hillen LM, et al. Optimizing Preclinical Models for Oral Cancer: The Influence of 4NQO Administration Routes on Tumor Development. Cancers. 2025; 17(13):2108. https://doi.org/10.3390/cancers17132108

Van den Bosch, Jolien, Nuran Caz, Sandrina Martens, Céline Erens, Leen Rasking, Pascal Gervois, Kim Nijsten, Uwe Himmelreich, Sofie Van Cauter, Lisa M. Hillen, and et al. 2025. "Optimizing Preclinical Models for Oral Cancer: The Influence of 4NQO Administration Routes on Tumor Development" Cancers 17, no. 13: 2108. https://doi.org/10.3390/cancers17132108

Van den Bosch, J., Caz, N., Martens, S., Erens, C., Rasking, L., Gervois, P., Nijsten, K., Himmelreich, U., Van Cauter, S., Hillen, L. M., Plasschaert, H., Lambrichts, I., & Wolfs, E. (2025). Optimizing Preclinical Models for Oral Cancer: The Influence of 4NQO Administration Routes on Tumor Development. Cancers, 17(13), 2108. https://doi.org/10.3390/cancers17132108